Logo image of ZURA

ZURA BIO LTD (ZURA) Stock Fundamental Analysis

NASDAQ:ZURA - Nasdaq - KYG9TY5A1016 - Common Stock

1.815  +0.02 (+1.4%)

Fundamental Rating

3

Taking everything into account, ZURA scores 3 out of 10 in our fundamental rating. ZURA was compared to 572 industry peers in the Biotechnology industry. While ZURA has a great health rating, there are worries on its profitability. ZURA has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

ZURA had negative earnings in the past year.
ZURA had a negative operating cash flow in the past year.
ZURA Yearly Net Income VS EBIT VS OCF VS FCFZURA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 0 -20M -40M -60M

1.2 Ratios

ZURA has a Return On Assets of -22.54%. This is in the better half of the industry: ZURA outperforms 74.51% of its industry peers.
Looking at the Return On Equity, with a value of -27.85%, ZURA belongs to the top of the industry, outperforming 80.35% of the companies in the same industry.
Industry RankSector Rank
ROA -22.54%
ROE -27.85%
ROIC N/A
ROA(3y)-20.43%
ROA(5y)N/A
ROE(3y)-36.26%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ZURA Yearly ROA, ROE, ROICZURA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 0 -20 -40 -60 -80 -100

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ZURA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ZURA Yearly Profit, Operating, Gross MarginsZURA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023

More info and screens

7

2. Health

2.1 Basic Checks

Compared to 1 year ago, ZURA has more shares outstanding
Compared to 1 year ago, ZURA has a worse debt to assets ratio.
ZURA Yearly Shares OutstandingZURA Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 10M 20M 30M 40M
ZURA Yearly Total Debt VS Total AssetsZURA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 50M 100M

2.2 Solvency

ZURA has an Altman-Z score of 1.10. This is a bad value and indicates that ZURA is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of ZURA (1.10) is better than 67.26% of its industry peers.
ZURA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 1.1
ROIC/WACCN/A
WACCN/A
ZURA Yearly LT Debt VS Equity VS FCFZURA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 0 50M 100M

2.3 Liquidity

ZURA has a Current Ratio of 10.36. This indicates that ZURA is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 10.36, ZURA belongs to the top of the industry, outperforming 81.77% of the companies in the same industry.
ZURA has a Quick Ratio of 10.36. This indicates that ZURA is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of ZURA (10.36) is better than 81.77% of its industry peers.
Industry RankSector Rank
Current Ratio 10.36
Quick Ratio 10.36
ZURA Yearly Current Assets VS Current LiabilitesZURA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 20M 40M 60M 80M 100M

More info and screens

1

3. Growth

3.1 Past

ZURA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 86.21%, which is quite impressive.
EPS 1Y (TTM)86.21%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-44.44%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 18.05% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y74.94%
EPS Next 2Y31.12%
EPS Next 3Y18.05%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ZURA Yearly Revenue VS EstimatesZURA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 1M 2M 3M 4M 5M
ZURA Yearly EPS VS EstimatesZURA Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 -0.5 -1 -1.5 -2 -2.5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ZURA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ZURA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ZURA Price Earnings VS Forward Price EarningsZURA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ZURA Per share dataZURA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2

4.3 Compensation for Growth

A more expensive valuation may be justified as ZURA's earnings are expected to grow with 18.05% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y31.12%
EPS Next 3Y18.05%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ZURA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ZURA BIO LTD

NASDAQ:ZURA (1/22/2025, 2:09:19 PM)

1.815

+0.02 (+1.4%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-07 2024-11-07/bmo
Earnings (Next)N/A N/A
Inst Owners53.51%
Inst Owner ChangeN/A
Ins Owners7.9%
Ins Owner Change-0.25%
Market Cap118.50M
Analysts85.71
Price Target14.57 (702.75%)
Short Float %11.13%
Short Ratio10
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-58.96%
Min EPS beat(2)-106.68%
Max EPS beat(2)-11.24%
EPS beat(4)2
Avg EPS beat(4)-1.8%
Min EPS beat(4)-106.68%
Max EPS beat(4)91.57%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-4.76%
PT rev (3m)-7.41%
EPS NQ rev (1m)0%
EPS NQ rev (3m)3.19%
EPS NY rev (1m)0%
EPS NY rev (3m)-38.08%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.77
P/tB 0.77
EV/EBITDA N/A
EPS(TTM)-0.64
EYN/A
EPS(NY)-0.75
Fwd EYN/A
FCF(TTM)-0.4
FCFYN/A
OCF(TTM)-0.33
OCFYN/A
SpS0
BVpS2.34
TBVpS2.34
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -22.54%
ROE -27.85%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-20.43%
ROA(5y)N/A
ROE(3y)-36.26%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 10.36
Quick Ratio 10.36
Altman-Z 1.1
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)86.21%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-44.44%
EPS Next Y74.94%
EPS Next 2Y31.12%
EPS Next 3Y18.05%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y4.17%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-2076.53%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-1660.83%
OCF growth 3YN/A
OCF growth 5YN/A